<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments on: Docs And Industry: A Cozy Relationship</title>
	<atom:link href="http://www.pharmalot.com/2007/04/docs_and_industry_a_cozy_relat/feed" rel="self" type="application/rss+xml" />
	<link>http://www.pharmalot.com/2007/04/docs_and_industry_a_cozy_relat/</link>
	<description>News, Comment and Conversation</description>
	<pubDate>Fri, 10 Feb 2012 15:54:05 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6.2</generator>
		<item>
		<title>By: ed</title>
		<link>http://www.pharmalot.com/2007/04/docs_and_industry_a_cozy_relat/#comment-3276</link>
		<dc:creator>ed</dc:creator>
		<pubDate>Sun, 29 Apr 2007 22:35:08 +0000</pubDate>
		<guid isPermaLink="false">http://plt.starledger.webfactional.com/2007/04/docs_and_industry_a_cozy_relat/#comment-3276</guid>
		<description>Dear Anonymous,

I understand your point, and it's a good one. I think the study authors are more concerned situations in which free samples of expensive brand-name meds are distributed while, at the same time, less expensive generics may fill the same need. And in that scenario, the insurance co-pay may be higher for the brand-name med, which the patient may choose to continue using, instead of trying the lower-cost generic.

Hope this helps,
ed
</description>
		<content:encoded><![CDATA[<p>Dear Anonymous,</p>
<p>I understand your point, and it&#8217;s a good one. I think the study authors are more concerned situations in which free samples of expensive brand-name meds are distributed while, at the same time, less expensive generics may fill the same need. And in that scenario, the insurance co-pay may be higher for the brand-name med, which the patient may choose to continue using, instead of trying the lower-cost generic.</p>
<p>Hope this helps,<br />
ed</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Anonymous</title>
		<link>http://www.pharmalot.com/2007/04/docs_and_industry_a_cozy_relat/#comment-3275</link>
		<dc:creator>Anonymous</dc:creator>
		<pubDate>Sun, 29 Apr 2007 14:55:48 +0000</pubDate>
		<guid isPermaLink="false">http://plt.starledger.webfactional.com/2007/04/docs_and_industry_a_cozy_relat/#comment-3275</guid>
		<description>I go to my doctor and do not have insurance. He charges me $50 for the visit and gives me samples for free. I appreciate that he helps me with the visit and gives me the medications for free. What else do you suggest that I do if he did not get samples from reps?</description>
		<content:encoded><![CDATA[<p>I go to my doctor and do not have insurance. He charges me $50 for the visit and gives me samples for free. I appreciate that he helps me with the visit and gives me the medications for free. What else do you suggest that I do if he did not get samples from reps?</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Melody</title>
		<link>http://www.pharmalot.com/2007/04/docs_and_industry_a_cozy_relat/#comment-3274</link>
		<dc:creator>Melody</dc:creator>
		<pubDate>Thu, 26 Apr 2007 00:38:24 +0000</pubDate>
		<guid isPermaLink="false">http://plt.starledger.webfactional.com/2007/04/docs_and_industry_a_cozy_relat/#comment-3274</guid>
		<description>Doctors STILL are the only point of interface between patients and prescription drugs. A bit (or a lot) of transparency needs to be inserted into this interaction. Perhaps doctors should get off their "entitlement" throne and really consider patient welfare before their own.</description>
		<content:encoded><![CDATA[<p>Doctors STILL are the only point of interface between patients and prescription drugs. A bit (or a lot) of transparency needs to be inserted into this interaction. Perhaps doctors should get off their &#8220;entitlement&#8221; throne and really consider patient welfare before their own.</p>
]]></content:encoded>
	</item>
</channel>
</rss>

<!-- Dynamic Page Served (once) in 0.150 seconds -->

